Pharmaceutical major Lupin is reportedly in advanced talks to sign a blockbuster deal with Merck Serono. According to the deal, Lupin will manufacture Merck Serono’s $1.5 billion worth branded mature drugs at its facilities.
Moreover, the company will also get marketing rights for the drugs for emerging countries and European markets. Merck Serono will retain the rights to market these drugs in the developed markets.
Recently, Lupin entered into definitive distribution agreement with Salix Pharmaceuticals under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
